OMICS and brain tumour biomarkers.
Currently, brain tumours are diagnosed by surgical biopsy and light microscopic examination of tissue, with immunohistochemistry in difficult cases. We review research in the field of brain tumour diagnosis and discuss several new approaches. In future, tumour type, optimal treatment, and prognosis could be obtained by studying the gene (genomics), protein (proteomics) or metabolite (metabolomics) content of tumour cells. These techniques generate complex data, analysed using techniques such as pattern recognition software to identify biomarker signatures of different tumours. Compared with individual biomarkers, biomarker signatures appear to increase diagnostic accuracy and may produce an improved brain tumour classification system.
Petrik
Vladimir
V
Centre for Clinical Neuroscience, Division of Cardiac and Vascular Sciences, St George's University of London, UK.
Loosemore
Alison
A
Howe
Franklyn A
FA
Bell
B Anthony
BA
Papadopoulos
Marios C
MC
D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D001932:Brain Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology*; D002555:Cerebrospinal Fluid / Q000737:chemistry; D005819:Genetic Markers; D023281:Genomics / Q000379:methods; D006801:Humans; D016571:Neural Networks, Computer; D020411:Oligonucleotide Array Sequence Analysis; D010363:Pattern Recognition, Automated; D040901:Proteomics / Q000379:methods; D012984:Software
D014408:Biomarkers, Tumor; D005819:Genetic Markers